ETFIS Series Trust I (PFFR) NPORT-P Virtus LifeSci Biotech Products ETF (Jan 2024 report)

Schedule of Investments - Virtus LifeSci Biotech Products ETF 

January 31, 2024 (unaudited)

Security Description	Shares		Value
COMMON STOCKS - 99.2%
Health Care - 99.2%
ACADIA Pharmaceuticals, Inc.*		11,625	$	301,204
ADMA Biologics, Inc.*		80,743		419,056
Agios Pharmaceuticals, Inc.*		14,036		317,494
Alnylam Pharmaceuticals, Inc.*		1,749		302,420
Amgen, Inc.		1,181		371,141
Amicus Therapeutics, Inc.*		26,201		325,678
Amylyx Pharmaceuticals, Inc.*		22,130		354,080
Apellis Pharmaceuticals, Inc.*		6,251		395,626
Ascendis Pharma A/S (Denmark)*(1)		2,716		352,890
Aurinia Pharmaceuticals, Inc. (Canada)*		36,124		272,375
Axsome Therapeutics, Inc.*(2)		4,452		400,814
BeiGene Ltd. (China)*(1)		1,739		257,772
BioCryst Pharmaceuticals, Inc.*		50,731		268,874
Biogen, Inc.*		1,272		313,751
BioMarin Pharmaceutical, Inc.*		3,342		294,363
BioNTech SE (Germany)*(1)		3,138		298,235
Bluebird Bio, Inc.*		98,849		100,826
Blueprint Medicines Corp.*		3,892		309,531
Bridgebio Pharma, Inc.*		9,084		311,490
CRISPR Therapeutics AG (Switzerland)*		5,183		326,270
Deciphera Pharmaceuticals, Inc.*		20,606		295,078
Exelixis, Inc.*		13,994		304,509
Gilead Sciences, Inc.		3,989		312,179
Halozyme Therapeutics, Inc.*		8,269		279,906
Harmony Biosciences Holdings, Inc.*		9,657		304,582
Immunocore Holdings PLC (United Kingdom)*(1)(2)		5,104		368,968
Incyte Corp.*		5,110		300,315
Insmed, Inc.*		11,295		314,001
Intra-Cellular Therapies, Inc.*		4,994		336,296
Ionis Pharmaceuticals, Inc.*		6,548		336,502
Ironwood Pharmaceuticals, Inc.*		28,489		404,259
Kiniksa Pharmaceuticals Ltd. Class A*		19,132		337,297
Legend Biotech Corp.*(1)		5,314		292,589
Lexicon Pharmaceuticals, Inc.*(2)		250,923		469,226
Ligand Pharmaceuticals, Inc.*		4,818		352,196
Mirum Pharmaceuticals, Inc.*		9,430		249,518
Moderna, Inc.*		3,799		383,889
Neurocrine Biosciences, Inc.*		2,688		375,702
Omniab, Inc. - $12.50 Earnout*(3)		1,295		0
Omniab, Inc. - $15.00 Earnout*(3)		1,295		0
PTC Therapeutics, Inc.*		11,819		308,358
Regeneron Pharmaceuticals, Inc.*		372		350,714
Rhythm Pharmaceuticals, Inc.*		7,597		335,104
Roivant Sciences Ltd.*(2)		29,308		293,080
Sage Therapeutics, Inc.*		15,380		394,343
Sarepta Therapeutics, Inc.*		3,451		410,634
SpringWorks Therapeutics, Inc.*		9,406		415,087
Tarsus Pharmaceuticals, Inc.*		17,061		464,742
Theravance Biopharma, Inc.*		29,628		280,873
Travere Therapeutics, Inc.*(2)		37,798		337,536
Ultragenyx Pharmaceutical, Inc.*		7,105		313,402
United Therapeutics Corp.*		1,284		275,777
Vertex Pharmaceuticals, Inc.*		802		347,571
Zai Lab Ltd. (China)*(1)(2)		10,798		232,913
Total Health Care				17,071,036
Total Common Stocks
(Cost $16,636,740)				17,071,036
SECURITIES LENDING COLLATERAL - 2.9%
Money Market Fund - 2.9%
Dreyfus Government Cash Management Fund, Institutional Shares, 5.22%(4)(5)
(Cost $501,844)		501,844		501,844
TOTAL INVESTMENTS - 102.1%
(Cost $17,138,584)				17,572,880
Liabilities in Excess of Other Assets - (2.1)%				(354,566	)
Net Assets - 100.0%			$	17,218,314

*	Non-income producing security.
(1)	American Depositary Receipts.
(2)	All or a portion of the security was on loan. The aggregate market value of securities on loan was $1,729,800; total market value of collateral held by the Fund was $1,813,631. Market value of the collateral held includes non-cash U.S. Treasury securities having a value of $1,311,787.
(3)	Security valued at fair value as determined in good faith by or under the direction of the Trustees. This security is disclosed as a Level 2 security in the Fair Value Hierarchy table located after the Schedule of Investments.
(4)	Represents securities purchased with cash collateral received for securities on loan.
(5)	The rate shown reflects the seven-day yield as of January 31, 2024.

Schedule of Investments - Virtus LifeSci Biotech Products ETF (continued) 

January 31, 2024 (unaudited)

Fair Value Measurements 

The Fund utilizes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 includes unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access. Level 2 includes observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data. Level 3 includes unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following table summarizes valuation of the Fund’s investments under the fair value hierarchy levels as of January 31, 2024.

	Level 1		Level 2		Level 3		Total
Asset Valuation Inputs
Common Stocks	$	17,071,036	$	0	$	—	$	17,071,036
Money Market Fund		501,844		—		—		501,844
Total	$	17,572,880	$	0	$	—	$	17,572,880